AVEO: AVEO Oncology kidney cancer combo fails at Phase III
Despite the combo failure, AVEO says that the control arm of Fotivda alone showed statistically significant progression free survival. The post AVEO Oncology kidney cancer combo fails at Phase III appeared first on Clinical Trials Arena.
Read full article »
AVEO is a Massachusetts-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.
Read more